ACELRX PHARMACEUT. DL-01 (F:R5XA) — Market Cap & Net Worth
Market Cap & Net Worth: ACELRX PHARMACEUT. DL-01 (R5XA)
ACELRX PHARMACEUT. DL-01 (F:R5XA) has a market capitalization of $38.92 Million (€33.29 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22922 globally and #2004 in its home market, demonstrating a -2.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACELRX PHARMACEUT. DL-01's stock price €1.00 by its total outstanding shares 51899648 (51.90 Million). Also see R5XA asset base for a full breakdown of the balance sheet.
ACELRX PHARMACEUT. DL-01 Market Cap History: 2015 to 2026
ACELRX PHARMACEUT. DL-01's market capitalization history from 2015 to 2026. Data shows change from $4.13 Billion to $60.68 Million (-31.92% CAGR). Also see ACELRX PHARMACEUT. DL-01 (R5XA) cash conversion ratio for how efficiently the company converts equity into cash flow.
ACELRX PHARMACEUT. DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACELRX PHARMACEUT. DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ACELRX PHARMACEUT. DL-01 stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1928.63x
ACELRX PHARMACEUT. DL-01's market cap is 1928.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $520.12 Million | $2.82 Million | -$35.10 Million | 184.57x | N/A |
| 2023 | $43.99 Million | $651.00K | -$18.40 Million | 67.57x | N/A |
| 2025 | $54.00 Million | $28.00K | -$14.29 Million | 1928.63x | N/A |
Competitor Companies of R5XA by Market Capitalization
Companies near ACELRX PHARMACEUT. DL-01 in the global market cap rankings as of September 19, 2026. Review R5XA tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ACELRX PHARMACEUT. DL-01 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
ACELRX PHARMACEUT. DL-01 Historical Marketcap From 2015 to 2026
Between 2015 and today, ACELRX PHARMACEUT. DL-01's market cap moved from $4.13 Billion to $ 60.68 Million, with a yearly change of -31.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €60.68 Million | +12.36% |
| 2025 | €54.00 Million | +79.07% |
| 2024 | €30.16 Million | -31.45% |
| 2023 | €43.99 Million | -62.93% |
| 2022 | €118.68 Million | -77.18% |
| 2021 | €520.12 Million | -54.57% |
| 2020 | €1.14 Billion | -51.94% |
| 2019 | €2.38 Billion | -6.08% |
| 2018 | €2.54 Billion | +30.62% |
| 2017 | €1.94 Billion | -36.41% |
| 2016 | €3.05 Billion | -26.00% |
| 2015 | €4.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ACELRX PHARMACEUT. DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.92 Million USD |
| MoneyControl | $38.92 Million USD |
| MarketWatch | $38.92 Million USD |
| marketcap.company | $38.92 Million USD |
| Reuters | $38.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more